Pharmacoeconomics and Pharmaceutical Economics Commons^™

Racial And Ethnic Differences In The Receipt Of Metabolic Syndrome Risk Factor Screening And Treatment Among Prostate Cancer Patients Treated With Androgen Deprivation Therapy., Yazan K. Barqawi

Pharmaceutical Sciences ETDs

Background: Racial and ethnic health disparities in prostate cancer prevalence, incidence, mortality, quality of life, screening, and treatment constitute the largest of all cancer disparities. These health disparities are associated with higher morbidity and mortality rates in minority populations. Treatment with androgen deprivation therapy (ADT) has been the most widely used therapeutic modality to reduce the progression of prostate cancer to a worse disease stage and relieve potential obstructive symptoms. However, ADT is associated with possible toxic metabolic and cardiovascular (CVS) adverse events that may occur within six months of ADT initiation. These adverse events include metabolic syndrome, type II …

Cost Effectiveness Analysis Of Enzalutamide, Abiraterone Plus Prednisone And Cabazitaxel Plus Predinsone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi

Pharmaceutical Sciences ETDs

Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. Of those diagnosed with prostate cancer, about 10-20 % will develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and 70 % of those cases will metastasize to mCRPC. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020; making prostate cancer the fifth most costly cancer.

Objective: To conduct a cost-effective analysis …

Cost-Effectiveness Analysis Of Enzalutamide, Abiraterone Acetate Plus Prednisone, Cabazitaxel Plus Prednisone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi

Shared Knowledge Conference

Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020. Objective: To conduct a cost-effective analysis of visceral mCRPC therapies post-docetaxel failure from a US healthcare payer perspective utilizing life-time horizon Markov model. These medications received highest National Comprehensive Cancer Network guideline recommendation to treat visceral mCRPC post-docetaxel failure. Methods: A pharmacoeconomic model was …